Durvalumab with carboplatin and paclitaxel with or without olaparib for newly diagnosed advanced or reccurent endometrial cancer

Durvalumab in combination with carboplatin and paclitaxel and/or olaparib is currently in clinical development for the treatment of endometrial cancer. Endometrial cancer, also referred to as uterine or womb cancer, is the presence of cancer cells on the lining of the womb. It is the 4th most common cancer among women in the UK. Symptoms of endometrial cancer include abnormal bleeding from the vagina, pain during sex, and lower back pain. Increasing age and higher levels of oestrogens are some of the risk factors associated with endometrial cancer. There is an unmet need for advanced treatments that offer survival benefits among endometrial cancer patients.